Evotec SE Financials

EVO Stock  USD 3.64  0.05  1.39%   
Based on the measurements of operating efficiency obtained from Evotec SE's historical financial statements, Evotec SE ADR is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Evotec SE's Property Plant And Equipment Net is very stable compared to the past year. As of the 19th of March 2025, Net Debt is likely to grow to about 139.2 M, while Common Stock Shares Outstanding is likely to drop about 188.5 M. Key indicators impacting Evotec SE's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.532.24
Way Up
Pretty Stable
Investors should never underestimate Evotec SE's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Evotec SE's cash flow, debt, and profitability to make informed and accurate decisions about investing in Evotec SE ADR.

Net Income

(91.67 Million)

  
Understanding current and past Evotec SE Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Evotec SE's financial statements are interrelated, with each one affecting the others. For example, an increase in Evotec SE's assets may result in an increase in income on the income statement.

Evotec SE Stock Summary

Evotec SE competes with CorMedix, Sangamo Therapeutics, Aptose Biosciences, Corvus Pharmaceuticals, and Immutep. Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Evotec Se operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 4715 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS30050E1055
CUSIP30050E105
LocationGermany
Business AddressEssener Bogen 7,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.evotec.com
Phone49 40 560 81 0
CurrencyUSD - US Dollar

Evotec SE Key Financial Ratios

Evotec SE Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.5B2.2B2.3B2.3B2.3B2.4B
Other Assets58.0M62.3M79.3M1.01.151.09
Other Current Liab61.9M63.9M78.4M73.3M175.6M184.4M
Net Debt69.8M(186.4M)91.5M115.3M132.6M139.2M
Retained Earnings(434.2M)(216.4M)(392.4M)(476.3M)(476.3M)(500.1M)
Accounts Payable42.5M72.6M97.3M134.3M154.5M162.2M
Cash422.2M699.3M415.2M510.9M587.5M616.9M
Other Current Assets62.8M63.6M123.0M64.1M144.8M152.0M
Total Liab740.0M857.5M1.1B1.2B1.1B1.2B
Total Current Assets658.8M1.1B1.1B903.2M1.0B1.1B
Short Term Debt30.0M50.6M16.4M149.1M171.4M180.0M
Common Stock163.9M176.6M177.0M177.2M203.8M131.2M
Net Receivables136.9M153.3M275.8M204.1M123.4M77.7M
Inventory13.6M25.8M29.8M30.9M35.5M37.3M
Good Will247.4M257.6M274.8M275.6M317.0M332.8M
Intangible Assets98.0M30.9M23.8M15.5M17.8M16.9M
Other Liab93.2M82.6M69.6M70.7M63.6M61.8M
Net Tangible Assets79.0M102.9M375.9M1.1B1.3B1.3B
Long Term Debt331.0M326.3M328.3M307.1M353.2M266.0M
Net Invested Capital1.1B1.7B1.5B1.1B1.3B1.1B
Short Long Term Debt15.4M36.1M1.6M130.0M117.0M122.8M
Net Working Capital450.4M776.4M736.0M438.6M504.4M421.1M
Capital Stock163.9M176.6M177.0M177.2M203.8M182.3M

Evotec SE Key Income Statement Accounts

202020212022202320242025 (projected)
Operating Income48.5M27.3M12.5M(107.1M)(47.5M)(45.1M)
Ebit19.4M230.8M(167.7M)(7.3M)(68.9M)(65.4M)
Ebitda75.5M298.4M(86.1M)(7.2M)24.1M21.9M
Net Income6.3M215.5M(175.7M)(83.9M)(96.5M)(91.7M)
Income Tax Expense19.6M21.5M21.7M(40.7M)3.3M2.0M
Total Revenue500.9M618.0M751.4M781.4M898.6M943.6M
Gross Profit125.7M151.5M174.1M175.1M201.3M211.4M
Interest Expense8.5M9.3M13.2M11.7M13.5M14.2M
Research Development63.9M72.2M76.6M112.5M57.5M39.4M
Cost Of Revenue375.2M466.5M577.4M606.4M697.3M732.2M
Income Before Tax25.8M237.0M(154.0M)(103.8M)(80.6M)(76.6M)
Tax Provision19.6M21.5M21.7M3.3M3.8M3.6M
Net Interest Income(7.1M)(7.0M)(4.8M)(2.5M)(2.2M)(2.3M)
Interest Income1.3M2.3M8.3M9.3M10.7M11.2M

Evotec SE Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash145.5M276.7M(284.2M)95.8M110.1M115.6M
Free Cash Flow(54.4M)3.3M21.8M(182.0M)(179.6M)(170.6M)
Depreciation56.1M67.6M81.7M99.9M93.0M97.6M
Other Non Cash Items6.5M(171.5M)160.2M232.3M24.4M16.3M
Capital Expenditures99.1M118.9M181.4M216.0M248.4M260.8M
Net Income6.3M215.5M(175.7M)(83.9M)(96.5M)(91.7M)
End Period Cash Flow422.6M699.3M415.2M510.9M587.5M616.9M
Change To Inventory(1.4M)(3.6M)(11.7M)(4.4M)(4.0M)(3.8M)
Investments(38.8M)(117.1M)(415.8M)(13.3M)(12.0M)(12.6M)
Net Borrowings(79.3M)209.4M(5.2M)(5.9M)(5.3M)(5.0M)
Change To Netincome(31.2M)24.1M19.3M(158.6M)(142.7M)(135.6M)

Evotec Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Evotec SE's current stock value. Our valuation model uses many indicators to compare Evotec SE value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evotec SE competition to find correlations between indicators driving Evotec SE's intrinsic value. More Info.
Evotec SE ADR is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At this time, Evotec SE's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Evotec SE's earnings, one of the primary drivers of an investment's value.

Evotec SE ADR Systematic Risk

Evotec SE's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Evotec SE volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Evotec SE ADR correlated with the market. If Beta is less than 0 Evotec SE generally moves in the opposite direction as compared to the market. If Evotec SE Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Evotec SE ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Evotec SE is generally in the same direction as the market. If Beta > 1 Evotec SE moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Evotec SE Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Evotec SE's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Evotec SE growth as a starting point in their analysis.

Price Earnings To Growth Ratio

1.03

At this time, Evotec SE's Price Earnings To Growth Ratio is very stable compared to the past year.

Evotec SE March 19, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Evotec SE help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Evotec SE ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of Evotec SE ADR based on widely used predictive technical indicators. In general, we focus on analyzing Evotec Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Evotec SE's daily price indicators and compare them against related drivers.
When determining whether Evotec SE ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evotec SE's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evotec Se Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evotec Se Adr Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.53)
Revenue Per Share
2.1925
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.02)
Return On Equity
(0.16)
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.